Abstract
We herein successfully demonstrate the use of chiral isochalcogenoureas as Lewis Base catalysts for a variety of (4+2)-cycloaddition reactions of allenoates and different Michael acceptors. In all cases the same structural key-motive, a dihydropyran with a (Z)-configurated exocyclic double bond could be accessed as the major regio- and diastereoisomer in an enantioselective manner. Furthermore, these chiral dihydropyrans were successfully engaged in different follow-up transformations.
Keywords: Organocatalysis, Lewis Bases, Isochal-cogenoureas, Cycloadditions, Allenoates
Introduction
Oxygen-containing 6-ring heterocycles like pyrans and (partially) hydrogenated derivatives thereof are frequently encountered motives in biologically active (natural) products or serve as valuable building blocks and synthesis intermediates en route to pharmaceutically relevant targets (Scheme 1A).[1–5] Accordingly, the development of synthesis approaches to access structurally diverse 6-ring O-heterocycles in an asymmetric manner is an important task.[2,3] (Formal) (4+2)-cycloadditions provide direct access to 6-ring motives and have been successfully used to access chiral partially hydrogenated pyran derivatives via formal (4+2)-cycloadditions of enones.[3] Allenoates 1 are easily accessible versatile reagents which can undergo a multitude of different cyclization reactions.[6] Remarkably, when activated with (chiral) Lewis base catalysts[7] they can enter different (orthogonal) reaction pathways depending on the used catalysts and reaction partners,[8–13] thus giving access to a diverse chemical space relying on simple starting materials and catalysts. Numerous applications utilizing allenoates for formal cycloadditions have been reported but unfortunately the identification of suited chiral catalysts that allow for high reactivities and high enantioselectivities can sometimes be tedious.[14]
Scheme 1.
(Hydro)pyrans (A), isochalcogenoureas (B), our recently developed IChU-catalysed (4+2)-cycloaddition of allenoates 1 with acceptors 2 and the orthogonal reaction pathways accessible with different Lewis base catalysts (C), and the herein investigated generality of this process using different acceptors and allenoates (D).
Our group has a longstanding interest in allenoate chemistry and their utilization to access chiral O-heterocycles.[14] Recently we initiated a program focusing on the use of easily accessible bench stable isochalcogenoureas (IChUs) as catalysts for allenoate reactions.[13] Noteworthy, while these catalysts (Scheme 1B) have successfully been established for acyl-transfer reactions and C1 ammonium enolate transformations,[15] they have, to the best of our knowledge, until our recent study not been utilized for allenoate activation. After thorough investigations we realized that these organocatalysts hold indeed much promise for allenoate reactions, as they allowed for highly enantioselective unprecedented formal (4+2)-cycloadditions of allenoates 1 with acceptors 2.[13] More specifically, this protocol gave the (Z)-configured dihydropyrans 3 with high levels of diastereo- and enantioselectivities either using established isothioureas (ITUs) or the very recently introduced isoselenoureas (ISeU) as catalysts (Scheme 1C).[16,17] Remarkably, this outcome was in sharp contrast to reported studies on the reaction of 1 and 2 in the presence of tert. phosphines, which resulted in (3 + 2)-cyclizations, and tert. amines which gave rac-(E)-3 and the double bond isomers 4.[18,19] Based on these encouraging previous results, which demonstrated that ITUs and ISeUs allow for novel highly enantio- and diastereoselective (4+2)-cycloadditions of allenoates in an unprecedented manner, we were wondering if this concept can be applied more generally to other classes of acceptors and allenoates.
As outlined in this contribution, the IChU-catalyzed formal (4+2)-cycloaddition of allenoates and different enone-type acceptors 6–8 is indeed a pretty general process, always delivering the corresponding 3,4-dihydropyrans with a (Z)-configurated exocyclic double bond in good to excellent enantioselectivities. Furthermore, the use of α-branched allenoates 9 was equally well tolerated, underscoring the generality of this protocol (Scheme 1D).
Results and Discussion
We started by investigating the reaction of the β-CF3-containing enone 6 a with allenoates 1 a and 9 a (Table 1 gives an overview of the most significant results obtained using the well-established catalysts ITU1–3 and ISeU depicted in Figure 1).
Table 1. Optimization of the (4+2)-cycloaddition of starting material 6 a.[a].
| Entry | IChU (mol%) | Solv. | T [°C] | t [h] | yield [%][b] | er[c] |
|---|---|---|---|---|---|---|
| 1 a–>10 a | ||||||
| 1 | ITU1 (20) | PhMe | 80 | 22 | 74 | > 99:1 |
| 2 | ITU2 (20) | PhMe | 80 | 22 | 59 | > 99:1 |
| 3 | ITU3 (20) | PhMe | 80 | 22 | < 10 | n.d. |
| 4 | ISeU (20) | PhMe | 80 | 22 | 84 | > 99:1 |
| 5 | ITU1(20) | PhMe | 60 | 22 | 48 | > 99:1 |
| 6 | ITU1 (20) | CHCl3 | 80 | 22 | 61 | > 99:1 |
| 7 | ITU1 (20) | AcN | 80 | 22 | n.d.[d] | n.d. |
| 8 | ITU1 (20) | PhMe | 80 | 2 | 74 | > 99:1 |
| 9 | ITU1 (20)[e] | PhMe | 80 | 2 | 70 | > 99:1 |
| 10 | ITU1 (20) | PhMe | 100 | 2 | 72 | > 99:1 |
| 11 | ISeU (20) | PhMe | 80 | 2 | 84 | > 99:1 |
| 12 | ITU1 (10) | PhMe | 80 | 2 | 52 | > 99:1 |
| 13 | ISeU (10) | PhMe | 80 | 2 | 78 | > 99:1 |
| 9 a–>11 a | ||||||
| 14 | ISeU (20) | PhMe | 80 | 2 | 64 | > 99:1 |
| 15 | ITU1 (20) | PhMe | 80 | 2 | 48 | > 99:1 |
| 16 | ISeU (20) | PhMe | 80 | 22 | 71 | > 99:1 |
| 17 | ISeU (20)[f] | PhMe | 80 | 22 | 77 | > 99:1 |
| 18 | ITU1 (20)[f] | PhMe | 80 | 22 | 60 | > 99:1 |
| 19 | ITU1 (10)[f] | PhMe | 80 | 22 | 43 | > 99:1 |
| 20 | ISeU (10)[f] | PhMe | 80 | 22 | 68 | > 99:1 |
All reactions were run for the indicated time at the given temperature by using 0.1 mmol 6 a and the respective allenoate (1.3 eq.) in the stated solvent (0.04 M based on 6 a) unless otherwise noted.
Isolated yields.
Determined by HPLC using a chiral stationary phase. The absolute configuration of 10 a was assigned by single crystal X-ray analysis.[22,23]
Decomposition of starting materials.
Addition of 1 equiv. K2CO3.
Using 1.6 eq. 9 a.
Figure 1. Chiral IChU used in these investigations.
This transformation was chosen because it was previously shown by Smith’s group[20] that the reaction of compounds 6 with allenoates 1 in the presence of Cinchona alkaloids as chiral tert. amine Lewis base catalysts allows for the enantioselective syntheses of dihydropyrans 10 with (E)-configuration of the exocyclic double bond.[19] Keeping in mind our recently established orthogonal (Z)-selective IChU-catalysed allenoate protocol using enones 2 (please compare with Scheme 1C),[13] we were thus hoping for a similar (Z)-preference combined with a high enantioselectivity when employing the CF3-containing acceptors 6.
First attempts using 20 mol% HyperBTM (ITU1) supported our proposal by yielding the expected (4+2)-product 10 a in 74% with excellent enantioselectivity (> 99:1) and high Z-selectivity (> 95%) when carrying out the reaction under base-free conditions in toluene at 80 °C for approximately one day (entry 1). Testing other ITUs next (entries 1–3) showed the same trend as observed in our previous study,[13] with ITU1 being more active than ITU2 and the 5-ring-based ITU3 showing no reactivity at all (this can be rationalized by the lower nucleophilicity of ITU3 as compared to the 6-ring derivatives ITU1-2[21] and, in analogy to our recent study, supports again a mechanistic scenario where catalyst-addition to the allenoate is the rate-limiting step). Also very similarly to our previous observations, ISeU allowed for a slightly higher yield by maintaining the excellent levels of stereocontrol (entry 4). Further fine-tuning of reaction conditions (entries 5–11) showed that toluene is the solvent of choice and that addition of an external base has no positive effect on the yield (entry 9). Furthermore, the transformation is finished within 2 h when carried out at 80 °C (entries 10 and 11). Unfortunately however, lower catalyst loadings gave slightly lower yields, but without effecting the excellent enantioselectivities (entries 12 and 13).
Having established suited highly enantioselective (Z)-selective (4+2)-cycloaddition conditions for the parent allenoate 1 a, we next tested the α-branched allenoate 9 a (entries 14–20). Recently we found that such allenoates can serve as unique C1 synthons for formal (4+1)-cycloadditions with quinone methides under organophosphine catalysis.[14b,c] In these applications, the catalyst adds to the allenoate’s sp-carbon in the established manner but after a subsequent proton transfer the CH2-group of the α-substituent becomes nucleophilic and then adds to the vinylogous acceptor. Interestingly, back-cyclization (and catalyst release) then occurs via the same carbon,[14b,c] thus allowing for reaction pathways that differ significantly from established transformations of classical allenoates 1. Based on these observations, we were thus wondering if a similar reactivity can also be observed under ITU catalysis or if 9 a reacts in the same manner as established for 1 a. Right from the first experiments we realized that 9 a reacts indeed in the same highly enantio- and diastereo-selective (4+2)-fashion as 1 a in the presence of either ITU1 or ISeU (entries 14 and 15). However, conversion was incomplete after 2 h and thus the use of 9 a required longer reaction times (entry 16) and also benefitted from a slightly larger excess of 1.6 equiv. of the allenoate (entries 17 and 18). Lower catalyst loadings were again detrimental (entries 19 and 20) but overall, it can be stated that 9 a reacts like a decorated derivative of 1 a without “active” participation of the sidechain under IChU catalysis.
With suited conditions for the IChU-catalyzed (4+2)-cycloadditions of allenoates 1 a and 9 a with acceptor 6 a established, we next investigated the application scope of these transformations by using differently decorated acceptors 6, as well as varying the allenoate’s ester groups. As detailed in Scheme 2, these cycloadditions were found to be rather independent from the electronic properties of the acceptors (e. g. 10 b vs 10 c) and the steric effects (10 e vs 10 f and 11 d vs 11 e), giving access to various products 10 and 11 in good isolated yields and with excellent enantioselectivities. Furthermore, the minor (E)-diastereomers were also only detected in trace amounts, thus underscoring the generality of this process.
Scheme 2.
Application scope of the IChU-catalysed (4+2)-cycloaddition of allenoates 1 and 9 with acceptors 6 (the (R)-configuration of 10 a could be assigned by single crystal X-ray diffraction analysis[22,23] and all other derivatives were assigned in analogy).
Based on the excellent results obtained for acceptors 6, we focused on the isomeric CF3-containing enones 7 next. Interestingly, in this case we were again able to access the targeted (Z)-configurated (4+2)-cycloaddition products 12 a and 13 a with excellent enantioselectivities when using the parent starting material 7 a in the presence of ITU1 (Scheme 3). Unfortunately, the yields were limited to around 40–60% and even after a detailed screening of different conditions and catalysts we were not able to overcome this limitation. Even more surprising, ISeU resulted in a significantly reduced yield for 12 a only and did not provide 13 a at all. Analysis of the reaction mixtures showed that acceptor 7 a undergoes some oligomerization in the presence of IChUs, which accounts not only for the reduced yields, but also explains why the usually more reactive ISeU leads to even lower yields because of an increased rate of this oligomerization attributed to this catalyst’s higher nucleophilicity. Based on these less encouraging results, we did not explore the full application scope for different enones 7, but we quickly realized that electronic alterations of these acceptors, as outlined for 7 b and 7 c, are not well tolerated as only trace amounts of products were formed in these cases (Scheme 3).
Scheme 3. Use of acceptors 7.
Besides CF3-enones 6 and 7, we also investigated the suitability of barbiturate-based acceptors 8 for these IChU-catalyzed (4+2)-cycloadditions.[24] First reactions of derivative 8 a with allenoates 1 a and 9 a showed that these compounds can be successfully engaged in our (4+2)-cycloaddition protocol, delivering the dihydropyrans 14 a and 15 a with (Z)-configuration again (Table 2). A detailed screening of different catalysts and conditions for the reaction of 1 a showed that again ITU1 and ISeU deliver the best results with respect to yield and enantioselectivity (entires 1–8). Noteworthy, hereby ITU3 also allowed for good enantioselectivities (entry 3) but with clearly reduced conversion rates as compared to ITU1 (entry 1) and ISeU (entry 4). Unfortunately, the obtained enantioselectivities were limited to 86:14 er and thus clearly not as excellent as compared to 6 and 7 (vide supra). Further variations of catalyst loading, reaction temperature and time, and H2O content (entries 9–18) showed that elevated temperatures of 120 °C in combination with 10 mol% of catalyst allow for fast reactions yielding 14 a in around 90% yield within one hour (entries 15 and 16), but with 86:14 er only. Interestingly, addition of molecular sieves or spiking of additional H2O did not really influence the reaction (entries 17 and 18), underscoring the general robustness of this protocol. With the results for allenoate 1 a at hand, we then again tested the α-branched 9 a (entries 19–24). In this case reaction rate and er were lower and we found slightly adapted conditions (as compared to 1 a) with reduced temperature (80 °C), prolonged reaction time (22 h), and a larger excess of allenoate (1.6 equiv.; entries 22–24) being beneficial to obtain 15 a in reasonable yields and enantioselectivities in the presence of 10 mol% ISeU (entry 22). In this case larger catalyst loadings turned out to be not beneficial (entry 24) and ITU1 gave 15 a with comparable enantioselectivity but in lower yield only (entry 23).
Table 2. Optimization of the (4+2)-cycloaddition of starting material 8 a.[a].
| Entry | IChU (mol%) | Solv. | T [°C] | t [h] | yield [%][b] | er[c] |
|---|---|---|---|---|---|---|
| 1 a–>14 a | ||||||
| 1 | ITU1 (20) | PhMe | 80 | 22 | 75 | 80:20 |
| 2 | ITU2 (20) | PhMe | 80 | 22 | 74 | 78:22 |
| 3 | ITU3 (20) | PhMe | 80 | 22 | 26 | 86:14 |
| 4 | ISeU(20) | PhMe | 80 | 22 | 74 | 86:14 |
| 5 | ITU1 (20) | EtOAc | 80 | 22 | 47 | 78:22 |
| 6 | ITU1 (20) | CHCl3 | 80 | 22 | 76 | 79:21 |
| 7 | ITU1 (20) | MeCN | 80 | 22 | n.d.[d] | 80:20 |
| 8 | ITU1 (20) | THF | 66 | 22 | 29 | 80:20 |
| 9 | ITU1 (20) | PhMe[e] | 80 | 22 | 67 | 80:20 |
| 10 | ITU1 (10) | PhMe | 80 | 22 | 75 | 80:20 |
| 11 | ITU1 (5) | PhMe | 80 | 22 | 62 | 80:20 |
| 12 | ITU1 (10) | PhMe | 60 | 22 | 72 | 80:20 |
| 13 | ITU1 (10) | PhMe | 100 | 22 | 81 | 80:20 |
| 14 | ITU1 (10) | PhMe | 120 | 22 | 94 | 80:20 |
| 15 | ITU1 (10) | PhMe | 120 | 1 | 92 | 80:20 |
| 16 | ISeU (10) | PhMe | 120 | 1 | 96 | 86:14 |
| 17 | ISeU (10)[f] | PhMe | 120 | 1 | 83 | 86:14 |
| 18 | ISeU(10)[g] | PhMe | 120 | 1 | 87 | 86:14 |
| 9 a–>15 a | ||||||
| 19 | ISeU (10) | PhMe | 120 | 1 | 63 | 74:26 |
| 20 | ISeU (10) | PhMe | 120 | 22 | 67 | 72:28 |
| 21 | ISeU (10) | PhMe | 80 | 22 | 75 | 79:21 |
| 22 | ISeU (10)[h] | PhMe | 80 | 22 | 80 | 82:18 |
| 23 | ITU1 (10)[h] | PhMe | 80 | 22 | 48 | 82:18 |
| 24 | ISeU(20)[h] | PhMe | 80 | 22 | 85 | 74:26 |
All reactions were run for the indicated time at the given temperature by using 0.1 mmol 8 a and the respective allenoate (1.3 eq.) in the stated solvent (0.02 M based on 8 a) unless otherwise noted.
Isolated yields.
Determined by HPLC using a chiral stationary phase.
Decomposition of starting materials.
0.04 M.
Addition of 1 equiv. MS 4 Å.
Addition of 2 equiv. H2O.
Using 1.6 eq. 9 a.
With robust and moderately enantioselective conditions for the IChU-catalyzed (4+2)-cycloadditions of allenoates 1 a and 9 a with the parent acceptor 8 a at hand, we investigated the application scope for different allenoates and barbiturate acceptors 8. As summarized in Scheme 4, these cycloadditions were again rather robust, i. e. when using ISeU as the catalyst, delivering the majority of products 14 and 15 in comparable yields, with high (Z)-selectivity, and with moderate to good enantioselectivities. Noteworthy less reactive are electron poor substrates as illustrated for the low-yielding syntheses of products 14 g and 15 g. In addition, the N-substituent of acceptors 8 has a pronounced effect on the observed outcome as well, as illustrated by the reduced enantioselectivities obtained for product 14 q. We hereby also tested some γ-substituted allenoates and the corresponding products 14 r and 14 s could be accessed in high yields as well. Interestingly, the cis diastereoisomers (relative configuration assigned by NMR analysis) were always obtained with significantly higher enantioselectivities as compared to the trans diastereoisomers, a result which is in line with previous observations made for acceptors 2.[13]
Scheme 4. Application scope of the IChU-catalysed (4+2)-cycloaddition of allenoates 1 and 9 with acceptors 8 ([a] er of the minor trans diastereoisomer).
We have carried out detailed (computational) mechanistic investigations during our previous studies using acceptors 2 (Scheme 1C).[13] Based on the results obtained therein and the conceptually analogous experimental outcome obtained in the present study we propose a mechanistic scenario as outlined in Scheme 5. First the catalyst adds to the β-position of the allenoate giving the resonance-stabilized Int-A (we have previously detected these intermediates by MS analysis and found this step being the rate-determining one[13]). This intermediate then undergoes the stereo-defining 1,4-addition to the Michael acceptor with its γ-carbon (giving Int-B). Cyclization then gives Int-C which finally undergoes catalyst elimination, which sets the double bond configuration and gives the herein accessed dihydropyran products with their (Z)-configurated exocylic double bonds. It should be noted that it may also be possible that the catalyst undergoes 1,4-addition to the Michael acceptor first, which can be an explanation for the partial decomposition of acceptor 7 a (compare with Scheme 3). However this seems to be operational for selected very reactive compounds only, as we did not observe any reaction of the catalysts and acceptors 6 and 8 when carrying out control experiments (neither did we using compounds 2 before).
Scheme 5. Proposed mechanistic scenario.
Finally, we also explored the suitability of the herein accessed dihydropyrans for further manipulations (Schemes 6 and 7). First, the t-butyl ester-containing products 11 a, 14 j and 15 n could be successfully engaged in acidic hydrolysis reactions. Interestingly however, while 14 j and 15 n showed the expected t-butyl ester hydrolysis only (Scheme 7), compound 11 a underwent a simultaneous ester-hydrolysis/dihydropyran-hydrolysis process giving compound 16 as a mixture of diastereoisomers (Scheme 6).
Scheme 6. Further manipulations of CF3-dihydropyrans 10–12.
Scheme 7. Further manipulations of barbiturate-based dihydropyrans 14 and 15.
Besides these acidic hydrolysis reactions, we also succeeded in carrying out a variety of C=O and C=C doublebond reductions. For example, compounds 10 a and 12 a can be partially hydrogenated under homogeneous transition metal-catalysed conditions giving the dihydropyrans 17 and 18 in high yields, with excellent diastereoselectivities, and with no or only little erosion of enantiopurity (Scheme 6). Noteworthy, these compounds were also successfully accessed by Smith’s group starting from the analogous (E)-configurated starting materials[20] and comparison of our analytical details with their reported data further confirms the absolute configuration of compounds 10 a and 12 a. Gratifyingly, an analogous homogenous C=C bond hydrogenation of 15 b was possible as well (relative configuration of 23 was assigned by NOE correlations). We also tried to carry out heterogenous Pd/C-catalyzed hydrogenations which however were not possible to work selectively as they gave mainly several (unidentified) side products. In addition, it was also possible to reduce the ester functionalities of compounds 14 b and 15 b (giving products 21 and 22) by using an excess of LiBH4 (Scheme 6).
Conclusion
We herein successfully demonstrate the generality of our recently introduced isochalcogenourea-catalysed stereoselective allenoate (4+2)-cycloaddition protocol.[13] Using CF3-based enones 6 and 7 in combination with allenoates 1 and 9 allows for enantioselective syntheses of CF3-containing dihydropyrans 10–12 (usually > 99:1 er). In addition, barbiturate-based acceptors 8 could be successfully employed as well, albeit with reduced enantioselectivities only. In all these cases, independent of the used starting materials, the targeted allenoate γ-addition-based (4+2)-cycloaddition products were obtained almost exclusively and with very high (Z)-selectivity for the exocyclic double bond, thus underscoring the generality of this IChU-catalysed allenoate-activation protocol. Furthermore, there herein access chiral dihydropyrans could be successfully engaged in various follow-up manipulations.
Experimental Section[23]
General Procedure for the Syntheses of Products 10 and 11
Acceptors 6 (0.1 mmol, 1 eq.) and Lewis base catalyst (ITU1 or ISeU, 20 mol%) were transferred to a Schlenk flask and dissolved in PhMe (2.5 mL, 0.04 M) under N2 atmosphere at rt. Then, the respective allenoate (0.13 mmol, 1.3 eq. for allenoates 1 and 0.16 mmol, 1.6 eq. for allenoates 9) was added and the mixture was stirred at 80 °C for 2 h (when using 1) or for 22 h (using 9). The mixture was cooled to rt., filtered over a Na2SO4 plug (2 cm) and evaporated to dryness to obtain the crude products 10 or 11, respectively. The residue was purified by preparative TLC (heptanes/EtOAc, 2/1 for products 10, 5/1 for products 11) giving the cyclic products in the reported yields and enantiopurities.
General Procedures for the Syntheses of Barbiturate-Based-Products 14 and 15
The barbiturate acceptors 8 (0.1 mmol, 1 eq.) and the Lewis base catalyst (ITU1 or ISeU, 10 mol%) were transferred to a Schlenk flask and dissolved in toluene (5 mL, 0.02 M) under a N2 atmosphere at rt. Then, the respective allenoate (0.13 mmol, 1.3 eq. for allenoates 1 and 0.16 mmol, 1.6 eq. for allenoates 9) was added in one portion and the mixture was stirred at 120 °C for 1 h (when using 1) or at 80 °C for 22 h (using 9). Afterwards, the mixture was cooled to rt., filtered over a Na2SO4 plug (2 cm) and evaporated to dryness to obtain the crude products 14 or 15, respectively. The residues were purified by preparative TLC (heptanes/EtOAc, 1/1) giving the cyclic products in the reported yields and enantiopurities.
Supplementary Material
Acknowledgements
This research was generously supported by the Austrian Science Funds (FWF): Project No. P36004 (financial support through the matching funds program by the Austrian National Foundation for Research, Technology and Development and the Research Department of the State of Upper Austria). We are grateful to Prof. Markus Himmelsbach (JKU) for support with HRMS analyses.
References
- [1].For overviews on pyrans as anticancer scaffolds and further references:; a) Kumar D, Sharma P, Singh H, Nepali K, Gupta GK, Jain SK, N-Kang F. RSC Adv. 2017;7:36977–36999. [Google Scholar]; b) Grover P, Bhardwaj M, Mehta L, Kapoor G, Chawla PA. Anti-Cancer Agents Med Chem. 2022;22:3239–3268. doi: 10.2174/1871520621666211119090302. [DOI] [PubMed] [Google Scholar]
- [2].Selected reviews on the syntheses of (hydro)-pyran derivatives:; a) Boivin TLB. Tetrahedron. 1987;43:3309–3362. [Google Scholar]; b) Clarke PA, Santos S. Eur J Org Chem. 2006:2045–2053. [Google Scholar]; c) Budakoti A, Mondal PK, Verma P, Khamrai J. Beilstein J Org Chem. 2021;17:932–963. doi: 10.3762/bjoc.17.77. [DOI] [PMC free article] [PubMed] [Google Scholar]; d) Maddila S, Kerru N, Jonnalagadda SB. Molecules. 2022;27:6347. doi: 10.3390/molecules27196347. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [3].Desimoni G, Faita G, Quadrelli P. Chem Rev. 2018;118:2080–2248. doi: 10.1021/acs.chemrev.7b00322. [DOI] [PubMed] [Google Scholar]
- [4].For an illustrative overview on the use of dihydropyranes as building blocks:; Song W, Wang S, Tang W. Chem Asian J. 2017;12:1027–1042. doi: 10.1002/asia.201700212. [DOI] [PubMed] [Google Scholar]
- [5].a) Recio MC, Giner RM, Máñez S, Ríos JL. Planta Med. 1994;60:232–234. doi: 10.1055/s-2006-959465. [DOI] [PubMed] [Google Scholar]; b) Fareed J, Hoppensteadt D, Walenga J, Iqbal O, Ma Q, Jeske W, Sheikh T. Clin Pharmacokinet. 2003;42:1043–1057. doi: 10.2165/00003088-200342120-00003. [DOI] [PubMed] [Google Scholar]; c) Rocha DFO, Hamilton K, Goncalves CCS, Machado G, Marsaioli AJ. J Nat Prod. 2011;74:658–663. doi: 10.1021/np100719f. [DOI] [PubMed] [Google Scholar]; d) Ikematsu H, Kawai N. Expert Rev Anti-Infect Ther. 2011;9:851–857. doi: 10.1586/eri.11.112. [DOI] [PubMed] [Google Scholar]
- [6].a) Li X, Zhang C, Xu Z. Acc Chem Res. 2001;34:535–544. doi: 10.1021/ar000253x. [DOI] [PubMed] [Google Scholar]; b) Ma S. Chem Rev. 2005;105:2829–2872. doi: 10.1021/cr020024j. [DOI] [PubMed] [Google Scholar]; c) Cowen BJ, Miller SJ. Chem Soc Rev. 2009;38:3102–3116. doi: 10.1039/b816700c. [DOI] [PubMed] [Google Scholar]; d) Yu S, Ma S. Angew Chem Int Ed. 2012;51:3074–3112. doi: 10.1002/anie.201101460. [DOI] [PubMed] [Google Scholar]; e) Fan YC, Kwon O. Chem Commun. 2013;49:11588–11619. doi: 10.1039/c3cc47368f. [DOI] [PMC free article] [PubMed] [Google Scholar]; f) Xiao Y, Sung Z, Guo H, Kwon O. Beilstein J Org Chem. 2014;10:2089–2121. doi: 10.3762/bjoc.10.218. [DOI] [PMC free article] [PubMed] [Google Scholar]; g) Wang Z, Xu X, Kwon O. Chem Soc Rev. 2014;43:2927–2940. doi: 10.1039/c4cs00054d. [DOI] [PMC free article] [PubMed] [Google Scholar]; h) López F, Mascareñas J. Chem Soc Rev. 2014;43:2904–2915. doi: 10.1039/c4cs00024b. [DOI] [PubMed] [Google Scholar]; i) Li E-Q, Huang Y. Chem Commun. 2020;56:680–694. doi: 10.1039/c9cc08241g. [DOI] [PubMed] [Google Scholar]
- [7].For general reviews on chiral LB catalysis:; a) Gaunt MJ, Johansson CCC. Chem Rev. 2007;107:5596–5605. doi: 10.1021/cr0683764. [DOI] [PubMed] [Google Scholar]; b) Fu GC. Acc Chem Res. 2000;33:412–420. doi: 10.1021/ar990077w. [DOI] [PubMed] [Google Scholar]; c) France S, Guerin DJ, Miller SJ, Lectka T. Chem Rev. 2003;103:2985–3012. doi: 10.1021/cr020061a. [DOI] [PubMed] [Google Scholar]; d) Denmark SE, Beutner GL. Angew Chem Int Ed. 2008;47:1560–1638. doi: 10.1002/anie.200604943. [DOI] [PubMed] [Google Scholar]; e) Taylor JE, Bull SD, Williams JMJ. Chem Soc Rev. 2012;41:2109–2121. doi: 10.1039/c2cs15288f. [DOI] [PubMed] [Google Scholar]
- [8].For reviews on chiral phosphine organocatalysis:; a) Methot JL, Roush WR. Adv Synth Catal. 2004;346:1035–1050. [Google Scholar]; b) Voituriez A, Marinetti A, Gicquel M. Synlett. 2015;26:142–166. [Google Scholar]; c) Li H, Lu Y. Asian J Org Chem. 2017;6:1130–1145. [Google Scholar]; d) Guo H, Fan YC, Sun Z, Wu Y, Kwon O. Chem Rev. 2018;118:10049–10293. doi: 10.1021/acs.chemrev.8b00081. [DOI] [PMC free article] [PubMed] [Google Scholar]; e) Huang Y, Liao J, Wang W, Liu H, Guo H. Chem Commun. 2020;56:15235–15281. doi: 10.1039/d0cc05699e. [DOI] [PubMed] [Google Scholar]; f) Xie C, Smaligo AJ, Song X-R, Kwon O. ACS Cent Sci. 2021;7:536–558. doi: 10.1021/acscentsci.0c01493. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [9].For early approaches using chiral tert. amines for asymmetric allenoate-based reactions:; a) Denis J-B, Masson G, Retailleau P, Zhu J. Angew Chem Int Ed. 2011;50:5356–5360. doi: 10.1002/anie.201100706. [DOI] [PubMed] [Google Scholar]; b) Wang X, Fang T, Tong X. Angew Chem Int Ed. 2011;50:5361–5364. doi: 10.1002/anie.201100945. [DOI] [PubMed] [Google Scholar]; c) Ashtekar KD, Staples RJ, Borhan B. Org Lett. 2011;13:5732–5735. doi: 10.1021/ol202301f. [DOI] [PubMed] [Google Scholar]; d) Pei C-K, Jiang Y, Wei Y, Shi M. Angew Chem Int Ed. 2012;51:11328–11332. doi: 10.1002/anie.201206958. [DOI] [PubMed] [Google Scholar]; e) Pei C-K, Shi M. Chem Eur J. 2012;18:6712–6716. doi: 10.1002/chem.201200209. [DOI] [PubMed] [Google Scholar]
- [10].For studies illustrating the complementary outcomes using different Lewis base catalysts for allenoate activation:; a) Huang G-T, Lankau T, Yu C-H. J Org Chem. 2014;79:1700–1711. doi: 10.1021/jo402609v. [DOI] [PubMed] [Google Scholar]; b) Yang L-J, Li S, Wang S, Nie J, Ma J-A. J Org Chem. 2014;79:3547–3558. doi: 10.1021/jo500356t. [DOI] [PubMed] [Google Scholar]; c) Huang G-T, Lankau Z, Yu C-H. Org Biomol Chem. 2014;12:7297–7309. doi: 10.1039/c4ob01177e. [DOI] [PubMed] [Google Scholar]; d) Li Y, Du S, Du Z, Chen C. RSC Adv. 2016;6:82260–82269. [Google Scholar]
- [11].For pioneering reports on tert. amine-catalysed (asymmetric) allenoate (4+2)-cycloadditions accessing 3,4-dihydropyrans:; a) Ashtekar KD, Staples RJ, Borhan B. Org Lett. 2011;13:5732–5735. doi: 10.1021/ol202301f. [DOI] [PubMed] [Google Scholar]; b) Wang X, Fang T, Tong X. Angew Chem Int Ed. 2011;50:5361–5364. doi: 10.1002/anie.201100945. [DOI] [PubMed] [Google Scholar]; c) Pei CK, Jiang Y, Shi M. Org Biomol Chem. 2012;10:4355–4361. doi: 10.1039/c2ob25475a. [DOI] [PubMed] [Google Scholar]; d) Pei C-K, Jiang Y, Wei Y, Shi M. Angew Chem Int Ed. 2012;51:11328–11332. doi: 10.1002/anie.201206958. [DOI] [PubMed] [Google Scholar]
- [12].For selected reports on chiral phosphine-catalysed asymmetric allenoate (4+2)-cycloadditions accessing 3,4-dihydropyrans:; a) Yao W, Dou X, Lu Y. J Am Chem Soc. 2015;137:54–57. doi: 10.1021/ja5109358. [DOI] [PubMed] [Google Scholar]; b) Wang H, Lu W, Zhang J. Chem Eur J. 2017;23:13587–13590. doi: 10.1002/chem.201703368. [DOI] [PubMed] [Google Scholar]; c) Wang C, Jia H, Zhang C, Gao Z, Zhou L, Yuan C, Xiao Y, Guo H. J Org Chem. 2017;82:633–641. doi: 10.1021/acs.joc.6b02659. [DOI] [PubMed] [Google Scholar]; d) Wang Z, Wang T, Yao W, Lu Y. Org Lett. 2017;19:4126–4129. doi: 10.1021/acs.orglett.7b01936. [DOI] [PubMed] [Google Scholar]
- [13].Vogl LS, Mayr P, Robiette R, Waser M. Angew Chem Int Ed. 2024;63:e202315345. doi: 10.1002/anie.202315345. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [14].For recent studies form our group illustrating these challenges:; a) Eitzinger A, Zielke K, Widhalm M, Robiette R, Waser M. Asian J Org Chem. 2018;7:1620–1625. doi: 10.1002/ajoc.201800275. [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Zielke K, Waser M. Org Lett. 2018;20:768–771. doi: 10.1021/acs.orglett.7b03906. [DOI] [PMC free article] [PubMed] [Google Scholar]; c) Zielke K, Kovac O, Winter M, Pospisil J, Waser M. Chem Eur J. 2019;25:8163–8168. doi: 10.1002/chem.201901784. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [15].For reviews on isothiourea catalysis:; a) Merad J, Pons J-M, Chuzel O, Bressy C. Eur J Org Chem. 2016:5589–5610. [Google Scholar]; b) Birman VB. Aldrichimica Acta. 2016;49:23–33. [Google Scholar]; c) Hartley WC, O’Riordan TJC, Smith AD. Synthesis. 2017;49:3303–3310. [Google Scholar]; d) Biswas A, Mondal H, Maji MS. J Heterocycl Chem. 2020;57:3818–3844. [Google Scholar]; e) McLaughlin C, Smith AD. Chem Eur J. 2021;27:1533–1555. doi: 10.1002/chem.202002059. [DOI] [PMC free article] [PubMed] [Google Scholar]; f) Bitai J, Westwood MT, Smith AD. Org Biomol Chem. 2021;19:2366–2384. doi: 10.1039/d0ob02208j. [DOI] [PubMed] [Google Scholar]; Nimmo AJ, Young CM, Smith AD. g) In: Asymmetric Organocatalysis: New Strategies, Catalysts, and Opportunities. Albrecht L, Albrecht A, Dell’Amico L, editors. Wiley-VCH; 2023. Isothiourea Catalysis – New Opportunities for Asymmetric Synthesis; p. 151. [Google Scholar]
- [16].Seminal study on the use of isoselenoureas:; Young CM, Elmi A, Pascoe DJ, Morris RK, McLaughlin C, Woods AM, Frost AB, Houpliere A, Ling KB, Smith TK, Slawin AMZ, et al. Angew Chem Int Ed. 2020;59:3705–3710. doi: 10.1002/anie.201914421. [DOI] [PubMed] [Google Scholar]
- [17].For a recent application of such catalysts:; Stockhammer L, Craik R, Monkowius U, Cordes DB, Smith AD, Waser M. Chemistry. 2023;1:e202300015 [Google Scholar]
- [18].a) Xi Q-Z, Gan Z-J, Li E-Q, Duan Z. Eur J Org Chem. 2018:4917–4925. [Google Scholar]; b) Rong M, Gege S, Qiuzhen X, Liu Y, Er-Qing L, Zheng D. Chin J Org Chem. 2019;39:2196–2202. [Google Scholar]; c) Anwar S, Lin L-T, Srinivasadesikan V, Gudise VB, Chen K. RSC Adv. 2021;11:38648–38653. doi: 10.1039/d1ra07165c. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [19].The high (E)-selectivity for the exocyclic double bond of 3,4-dihydropyranes accessed via tert. amine catalysed (4+2)-cycloadditions of allenoates and enones is well-documented (Ref. 11).
- [20].Kasten K, Cordes DB, Slawin AMZ, Smith AD. Eur J Org Chem. 2016:3619–3624. [Google Scholar]
- [21].Maji B, Joanesse C, Nigst TA, Smith AD, Mayr H. J Org Chem. 2011;76:5104–5112. doi: 10.1021/jo200803x. [DOI] [PubMed] [Google Scholar]
- [22].Deposition number 2324831 (10 a) contains the supplementary crystallographic data for this paper. These data are provided free of charge by the joint Cambridge Crystallographic Data Centre and Fachinformationszentrum Karlsruhe Access Structures service.
- [23].Full experimental and analytical details can be found in the online supporting information.
- [24].For an allenoate (4+2)-cycloaddition with barbiturates where the barbiturate serves as a C2 building block:; Liu H, Liu Y, Yuan C, Wang G-P, Zhu S-F, Wu Y, Wang B, Sun Z, Xiao Y, Zhou Q-L, Guo H. Org Lett. 2016;18:1302–1305. doi: 10.1021/acs.orglett.6b00239. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.








